| Document |
Document Title |
|
WO/2013/111148A1 |
The present invention provides a process for preparation of Luteolin by deprotection of the corresponding ethers using Lewis acid mediated Ionic complexes, and to compositions containing the same.
|
|
WO/2013/109735A1 |
The invention provides tricyclic sulfone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated t...
|
|
WO/2013/104263A1 |
Provided is a polyhydroxy benzopyran ketone compound having the structure as represented by formula (I) and pharmaceutically acceptable salt or pro-drug thereof, as well as pharmaceutical composition containing the compound. The compound...
|
|
WO/2013/105037A1 |
The present invention describes the compound of general formula 1 (Formula 1) their salts or esters for the treatment of diseases that are positively influenced by the inhibition of p53-MDM2 or p53-MDMX interaction. In particular for the...
|
|
WO/2013/099982A1 |
A shikuwasa (Okinawa lime) extract, preferably an extract of a fruit or a leaf of shikuwasa with water and/or an organic solvent, a supercritical extract of a fruit or a leaf of shikuwasa or a subcritical extract of a fruit or a leaf of ...
|
|
WO/2013/100003A1 |
A method for purifying an oligomeric proanthocyanidin, comprising an extraction step of extracting a raw material containing multiple types of oligomeric proanthocyanidins having different degrees of polymerization with an extraction sol...
|
|
WO/2013/096223A1 |
Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds a...
|
|
WO/2013/096878A1 |
Embodiments of the present disclosure related to compounds and compositions derived from G. buchananii baker and methods thereof.
|
|
WO/2013/090921A1 |
Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP- 1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidi
n-l-yl]ethoxy}phenyl)-2H-chromen-7-o...
|
|
WO/2013/088455A1 |
Disclosed herein is single step process for the synthesis of 4-aryl substituted chromanes of compound of formula 2 comprising subjecting 3-aryloxy-l-phenylpropan-l-ol of formula 1 to gold (III) chloride-catalyzed intramolecular Friedel-C...
|
|
WO/2013/089197A1 |
[Problem] To provide: a xanthene compound which has characteristics such as high clarity and color developability, while exhibiting excellent fastness such as heat resistance; and a dye composition of the xanthene compound. [Solution] A ...
|
|
WO/2013/090220A1 |
The present invention relates to indeno-fused naphthopyrans, and in particular indeno[2',3':3,4]naphtho[1,2-b]pyrans having certain groups bonded to the 3, 6, 7, 11, and 13 positions thereof. The indeno-fused naphthopyrans of the present...
|
|
WO/2013/086621A1 |
The present document describes a method for extracting anthocyanin derivatives from a plant source. The method comprises the step of separating a homogenized extract of plant source in a polar acidified solvent for obtaining a residual s...
|
|
WO/2013/086248A1 |
The present invention relates to photochromic materials that include one or more indeno-fused naphthopyrans that have particular groups at the 7, 1 1, and 13 positions thereof, and at the position alpha to the oxygen of the pyran ring th...
|
|
WO/2013/083282A1 |
The invention relates to photochromic bis-indenofused naphthopyrans of the general formula (I) and to the use thereof in synthetic materials of all kinds, in particular for ophthalmic purposes. The photochromic compounds according to the...
|
|
WO/2013/083014A1 |
Disclosed is a daidzein derivative as represented by formula I, or pharmaceutically acceptable salt thereof. Compared to the daidzein in the prior art, the daidzein derivative hydrochloride, in particular to the 7-O-N, N-diethyl-aminoace...
|
|
WO/2013/081046A1 |
A compound shown by the general formula (1), and an antitumor agent containing this compound as an active ingredient. (A)n1-(B)n2… (1); where n1 represents any integer of 6-20, n2 represents any integer of 1-20, A is a group shown by t...
|
|
WO/2013/079223A1 |
The invention provides modulators for the orphan nuclear receptor RORϒ and methods for treating RORϒ mediated diseases by administrating these novel RORϒ modulators to a human or a mammal in need thereof. Specifically, the present inv...
|
|
WO/2013/078086A1 |
The present invention relates to photochromic compounds that include at least two photochromic moieties that are linked together by a multivalent linking group. The multivalent linking group can be selected so as to be flexible and/or su...
|
|
WO/2013/068275A1 |
The invention concerns a polymer-bonded polycyclic aromatic hydrocarbon compound of general formula (1): (P—O) x —Q—(Y) w (1) wherein P represents a polymeric moiety having at least three repeating units which comprise an optionall...
|
|
WO/2013/070998A1 |
Methods for inhibiting the growth of ovarian cancer cells or other serosal cancer cells are disclosed. The method involves exposing the cells to a 2-amino-4H-naphtho[1,2-b]pyran-3-carbonitrile of formula. (I). wherein Y is CR1 or N and Z...
|
|
WO/2013/066067A1 |
Disclosed are a phenol monomer, a polymer for forming a resist underlayer film including same, and a composition for a resist underlayer film including same, which are to be used in a semiconductor lithography process. The phenol monomer...
|
|
WO/2013/061999A1 |
Provided is a method for producing an optically active alcohol with high yield by an industrially advantageous process with use of a low-cost asymmetric catalyst, while using a ketone, which may have various structures, as a starting mat...
|
|
WO/2013/058644A1 |
The invention relates to the use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes. Said drug has the effect of lowering plasma glucose concentration following administration. Said drug in...
|
|
WO/2013/055647A1 |
Provided are various compounds comprising the formula Also provided are fluorescent dyes comprising the above compound. Additionally, a fluorescence energy transfer system is provided that comprises the above-described fluorescent dye an...
|
|
WO/2013/020184A9 |
Disclosed herein are flavonoid compounds of formula (I) with variables as defined herein, compositions containing these compounds, methods for their synthesis, and uses of these compounds. In particular, there is provided methods of prev...
|
|
WO/2013/052338A1 |
The present invention relates to photochromic materials that include certain indeno-fused naphthopyrans. The indeno-fused naphthopyrans have an amino group (e.g., a piperidino or morpholino group) bonded to the 6-position and hydrogen or...
|
|
WO/2013/045115A1 |
The invention relates to a compound selected from the group consisting of all stereoisomers and their mixtures of the compounds of general formulas (1)-(4), in which R1 is a straight-chained, branched or cyclic hydrocarbon group with up ...
|
|
WO/2013/048334A1 |
The present invention relates to use of a series of compounds and compositions comprising the same for enhancing telomerase expression and/or activating telomerase activity in a cell or tissue of a subject and for treatment of diseases, ...
|
|
WO/2013/041895A1 |
The invention relates to novel compounds of general formula (I), and their preparation, pharmaceutical preparations containing compounds of general formula (I), and the use of these compounds in therapeutic procedures. The invention also...
|
|
WO/2013/041655A1 |
Disclosed is a process for the preparation of a cinchonidine salt of formula (IV) via an aqueous solution of a racemic 4-hydroxy-1,2-cyclopentanedicarboxylic acid, which is subjected to cyclization without removing water, by the addition...
|
|
WO/2013/042800A1 |
Provided is a chromene compound which has a sulfur-containing substitute represented by formula (2) at the carbon atom in the 6-position and/or the 7-position of an indeno(2,1-f)naphtho(1,2-b)pyran structure. This chromene compound has e...
|
|
WO/2013/044118A2 |
This invention relates to novel coumarin derivatives, formulations comprising same, and to methods of making and using these compounds and formulations, which are useful as repellents against insects and/or pests. The compounds also prev...
|
|
WO/2013/036678A1 |
The present invention provides compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 is as defined and described herein, compositions thereof, and methods of using the same.
|
|
WO/2013/034756A1 |
The present invention relates to a compound of formula (I), wherein R1 and R2 are independently selected from (a) C1 to C6 alkyl; C2 to C6 alkenyl; C2 to C6 alkynyl; substituted or unsubstituted heterocycloalkyl or cycloalkyl, substituen...
|
|
WO/2013/036726A1 |
Methods for the production of enriched plant polyphenols-dairy (e.g., milk) or polyphenols-ground edible material products that can be used in the preparation of functional foods, dietary supplements, medical foods, cosmetic products or ...
|
|
WO/2013/035767A1 |
Provided is a compound represented by formula (I), which can be used as a fluorescent probe that becomes highly fluorescent only in an intracellular acidic environment and can be adapted to the fluorescent imaging of an intracellular ves...
|
|
WO/2013/036207A1 |
The present invention relates to xanthone analogs. Such compounds may be used in the treatment of bacterial infections.
|
|
WO/2013/031831A1 |
In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. ...
|
|
WO/2013/031838A1 |
The purpose of the present invention is to provide a novel compound having a specific xanthene derivative multimeric structure, and that provides a printed item having greater ozone resistance, light resistance, and other image durabilit...
|
|
WO/2013/032608A1 |
The present invention relates to compounds represented by the following Formulas (I) and (II), Ring-A of Formulas I and II can be, for example, an aryl group, and Q' and Q''' can each be independently selected from groups, such as, halog...
|
|
WO/2013/033377A1 |
Disclosed are novel isoflavone derivatives having the structure of Formula (I) which are ALDH-2 inhibitors, useful for treating a patient in need thereof, for dependence upon drugs of addiction, for example addiction to dopamine-producin...
|
|
WO/2013/026149A1 |
A compound dimethyl-(3,3-difluoro-2,2-dihydroxyheptyl)phosphonate (I), a crystalline form of this compound, processes for its preparation, and use of this compound in the preparation of prostaglandin derivatives such as Lubiprostone.
|
|
WO/2013/024778A1 |
A resist composition containing a compound represented by general formula (1) or (2), a resist pattern formation method using said resist composition, a polyphenol compound used in the resist pattern formation method, and an alcohol comp...
|
|
WO/2013/024779A1 |
Provided is a novel underlayer film-forming material and such for lithography, said material having a high carbon concentration and a low oxygen concentration, and exhibiting relatively high heat resistance and solvent solubility. Moreov...
|
|
WO/2013/020930A1 |
The present invention relates to aminochromane, aminothiochromane and 1,2,3,4-tetrahydroquinoline derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprisin...
|
|
WO/2013/021971A1 |
[Problem] To provide an organic photoelectric conversion element whereby conversion efficiency is increased by morphology reformation in a power generation layer, and whereby short-circuit current (Jsc) attenuation when emitting light is...
|
|
WO/2013/020979A1 |
The present invention relates generally to catechin and epicatechin conjugates of formula (I). For example, a chemical synthesis process for the preparation of catechin and epi-catechin compounds, in particular of catechin and epi-catech...
|
|
WO/2013/018053A1 |
The present invention relates to a novel process of synthesis of epoxides, 6-fluoro-2- (oxiran-2-yl) chroman (Figure 1), intermediates for the synthesis of nebivolol, depicted in Scheme (1), enabling to obtain the above- mentioned epoxid...
|
|
WO/2013/019686A2 |
Small molecule therapeutics for the treatment of parasitic diseases, in particular, semi-synthetic derivatives of the fugally-derived natural product merulin A for the treatment of African Sleeping Sickness.
|
